Category Archives: Ophthalmology

Review of nepafenac (Nevanac) ophtalmic suspension

Review form Health Canada of nepafenac (Nevanac) , a non-steroidal anti-inflammatory drug (NSAID) for the management of pain and inflammation associated with cataract surgery

On April 17, 2008, Health Canada issued a Notice of Compliance to Alcon Canada Inc. for the drug product, NevanacTM (nepafenac) Ophthalmic Suspension.

NevanacTM contains the medicinal ingredient nepafenac which is a nonsteroidal
anti-inflammatory drug (NSAID).

NevanacTM is indicated for the management of pain and inflammation associated with cataract surgery. After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac. Amfenac inhibits the action of prostaglandin H synthase (cyclooxygenase), an enzyme required to produce prostaglandin which causes pain and swelling in the eye.
Continue Reading

Off-label intravitreal use of bevacizumab (Avastin): reports of ocular side effects

Letter from Roche to health care professionals dated December 16, 2008. Related to off- label uses in ophtalmology of bevacizumab (Avastin): Reports of Eye Inflammation, Endophthalmitis, and Toxic Anterior Segment Syndrome (TASS) Following Off-label Intravitreal Use of AVASTIN® (bevacizumab)Continue Reading

Are you a visual learner interested in learning psychopharmacology? Click here to get our videos